Alvotech and Lotus Pharmaceutical Partner to Commercialize Biosimilars for Oncology and Hematology

Key Facts

In a move reflecting the ongoing expansion within the global biotechnology sector, Alvotech has announced a strategic commercial licensing agreement with Lotus Pharmaceutical. This partnership aims to commercialize two biosimilar candidates: AVT34, a proposed biosimilar to the oncology drug Imfinzi, and AVT87, a proposed biosimilar to the hematology treatment Hemlibra. According to reports, the agreement covers the United States and selected Asian markets, significantly broadening Alvotech's international commercial footprint.

The agreement strengthens the commercial portfolios of both companies in high-value medical segments, as Imfinzi generated approximately $6.1 billion in global sales in 2025, while Hemlibra recorded sales of nearly $5.8 billion in the same year. Under the terms of the deal, Lotus Pharmaceutical will hold exclusive commercialization rights in eight Asian markets, including South Korea, Taiwan, Thailand, Vietnam, the Philippines, Singapore, Hong Kong, and Malaysia, leveraging its local expertise per market data and corporate disclosures.

While current price levels for ALVO stock are unavailable at this time, this collaboration serves as a positive catalyst for the company's long-term revenue outlook by securing a robust commercial platform in Asia. Investors will be monitoring the regulatory progress of these biosimilar candidates, while the economic calendar highlights upcoming data such as Canada's CPI and the U.S. NY Empire State Manufacturing Index on August 17, 2026, which may influence broader market sentiment in growth sectors.